Mucociliary Clearance from Central Airways in Patients with Excessive Sputum Production with and without Primary Ciliary Dyskinesia

CHEST Journal ◽  
1990 ◽  
Vol 98 (3) ◽  
pp. 608-612 ◽  
Author(s):  
Gerald L. Baum ◽  
S. Tzila Zwas ◽  
Ido Katz ◽  
Yehuda Roth
2019 ◽  
Vol 54 (12) ◽  
pp. 2021-2027
Author(s):  
Reza Vali ◽  
Hasan Ghandourah ◽  
Martin Charron ◽  
Kimiya V. Nezhad ◽  
Yusuaf Omarkhail ◽  
...  

2014 ◽  
Vol 44 (2) ◽  
pp. 533-535 ◽  
Author(s):  
W. T. Walker ◽  
A. Young ◽  
M. Bennett ◽  
M. Guy ◽  
M. Carroll ◽  
...  

2012 ◽  
Vol 50 (4) ◽  
pp. 353-359
Author(s):  
J. Rimmer

Mucociliary clearance is a primary defence mechanism of the airway that can be altered in congenital diseases such as primary ciliary dyskinesia and cystic fibrosis, as well as acquired conditions. This article focuses on primary ciliary dyskinesia and the diagnostic approach to it, which is still evolving.


2021 ◽  
Vol 18 ◽  
pp. 147997312110616
Author(s):  
Mathias G Holgersen ◽  
June K Marthin ◽  
Helle K Johansen ◽  
Kim G Nielsen

Objectives: Primary ciliary dyskinesia (PCD) is a rare congenital disease with defective mucociliary clearance causing frequent and often persistent pulmonary infections. Achromobacter species are opportunistic pathogens renowned for the difficulty of effective treatments and deteriorating effects on lung function. We aimed to describe the occurrence, treatment, and rate of successful eradication of Achromobacter species in patients with PCD. Methods: We retrospectively reviewed 18 years of historical microbiological samples and 10 years of electronic health records for PCD patients in Denmark. Results: We included 136 patients. Twenty-six patients had isolates of Achromobacter species. On average, 5% of the cohort had at least one annual isolate. Infections became persistent in 38% with a median length of 6.6 years leading to a significant number of antibiotic treatments. Resistance toward tobramycin and ciprofloxacin was prevalent. Overall, successful eradication was achieved in 62% of patients. We found the course of lung function significantly worse during persistent Achromobacter species infection than during the two preceding years, but not different to the course in unaffected age-matched controls. Conclusion The prevalence of Achromobacter species in patients with PCD is in line with what has been reported in cystic fibrosis and can occur transiently, intermittently, or develop into a serious persistent lung infection associated with long-term antibiotic treatment.


Author(s):  
Terry Robinson ◽  
Jane Scullion

Bronchiectasis is defined as irreversible bronchial wall dilatation and thickening. It may present clinically with recurrent chest infections, cough, chronic sputum production, shortness of breath, pleuritic chest pain, fatigue, and malaise. It can occur as a result of a primary infection, toxic insult occurring at any time from childhood to late adulthood, immunodeficiencies, some inflammatory conditions, and some inherited conditions such as primary ciliary dyskinesia and cystic fibrosis, but in approximately 50% of cases no underlying cause is found. This chapter covers the causes, clinical features, and management of bronchiectasis, including antibiotic treatment. Other infections that may occur are also explained, and monitoring regimes are indicated.


2019 ◽  
Vol 61 (3) ◽  
pp. 312-321 ◽  
Author(s):  
Weining Yin ◽  
Alessandra Livraghi-Butrico ◽  
Patrick R. Sears ◽  
Troy D. Rogers ◽  
Kimberlie A. Burns ◽  
...  

2021 ◽  
Vol 22 (18) ◽  
pp. 9834
Author(s):  
Tamara Paff ◽  
Heymut Omran ◽  
Kim G. Nielsen ◽  
Eric G. Haarman

Primary ciliary dyskinesia (PCD) is a rare genetic ciliopathy in which mucociliary clearance is disturbed by the abnormal motion of cilia or there is a severe reduction in the generation of multiple motile cilia. Lung damage ensues due to recurrent airway infections, sometimes even resulting in respiratory failure. So far, no causative treatment is available and treatment efforts are primarily aimed at improving mucociliary clearance and early treatment of bacterial airway infections. Treatment guidelines are largely based on cystic fibrosis (CF) guidelines, as few studies have been performed on PCD. In this review, we give a detailed overview of the clinical studies performed investigating PCD to date, including three trials and several case reports. In addition, we explore precision medicine approaches in PCD, including gene therapy, mRNA transcript and read-through therapy.


Respiration ◽  
1987 ◽  
Vol 52 (1) ◽  
pp. 69-75 ◽  
Author(s):  
S. van der Baan ◽  
A.J.P. Veermarn ◽  
G.A.K. Heidendahl ◽  
W. den Hollander ◽  
L. Feenstra

CHEST Journal ◽  
2007 ◽  
Vol 132 (3) ◽  
pp. 966-976 ◽  
Author(s):  
June Kehlet Marthin ◽  
Jann Mortensen ◽  
Tacjana Pressler ◽  
Kim Gjerum Nielsen

Sign in / Sign up

Export Citation Format

Share Document